Institute of Pharmacology and Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058 China.
Cancer Invest. 2010 Jan;28(1):23-32. doi: 10.3109/07357900903095664.
The present study demonstrates that the combination of TRAIL/APO-2L and celastrol exerts strong synergistic antiproliferative effect against human cancer cells including ovary cancer OVCAR-8, colon cancer SW620, and lung cancer 95-D, with the combination indices below 0.8. Moreover, the in vivo antitumor efficacy of TRAIL/APO-2L was dramatically increased by celastrol. These enhanced anticancer activities were accompanied by the prompt onset of caspase-mediated apoptosis. Taken together, our data firstly demonstrate the synergistic anticancer capabilities achieved by combining TRAIL/APO-2L and celastrol, and moreover, open new opportunities to enhance the effectiveness of future treatment regimens using TRAIL/APO-2L.
本研究表明，TRAIL/APO-2L 与雷公藤红素联合应用对包括卵巢癌 OVCAR-8、结肠癌 SW620 和肺癌 95-D 在内的多种人类癌细胞具有强大的协同抗增殖作用，其联合指数均低于 0.8。此外，雷公藤红素显著增强了 TRAIL/APO-2L 的体内抗肿瘤疗效。这些增强的抗癌活性伴随着 caspase 介导的凋亡的迅速发生。总之，我们的数据首次证明了 TRAIL/APO-2L 与雷公藤红素联合应用的协同抗癌能力，并为未来使用 TRAIL/APO-2L 的治疗方案的有效性提供了新的机会。
